Research statistics

Dulaglutide research: publications and trials

What has been published on Dulaglutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Dulaglutide works or is safe. For what it is and what the studies found, see the Dulaglutide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

1,082

Since 2010

Publications in 2026 so far

181

Through November 15, 2026

Human clinical research

53.6%

577 of 1,077 classified

Registered clinical trials

121

ClinicalTrials.gov

Randomized controlled trials

171

Publications reporting an RCT in people

Systematic reviews and meta-analyses

133

Preclinical studies

12.4%

76 animal · 16 in vitro · 42 computational

Records that only mention it

204

Not counted above

Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 5 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Dulaglutide publications by year and evidence

2010, Preclinical (animal, in vitro, computational): 1 of 22010, Reviews and meta-analyses: 1 of 22011, Human clinical research: 3 of 42011, Reviews and meta-analyses: 1 of 42012, Human clinical research: 4 of 42013, Reviews and meta-analyses: 3 of 32014, Human clinical research: 7 of 172014, Reviews and meta-analyses: 6 of 172014, Other and not yet classified: 4 of 172015, Human clinical research: 12 of 412015, Preclinical (animal, in vitro, computational): 3 of 412015, Reviews and meta-analyses: 22 of 412015, Other and not yet classified: 4 of 412016, Human clinical research: 16 of 432016, Preclinical (animal, in vitro, computational): 1 of 432016, Reviews and meta-analyses: 24 of 432016, Other and not yet classified: 2 of 432017, Human clinical research: 17 of 402017, Preclinical (animal, in vitro, computational): 4 of 402017, Reviews and meta-analyses: 18 of 402017, Other and not yet classified: 1 of 402018, Human clinical research: 30 of 642018, Preclinical (animal, in vitro, computational): 6 of 642018, Reviews and meta-analyses: 21 of 642018, Other and not yet classified: 7 of 642019, Human clinical research: 36 of 682019, Preclinical (animal, in vitro, computational): 16 of 682019, Reviews and meta-analyses: 10 of 682019, Other and not yet classified: 6 of 682020, Human clinical research: 45 of 892020, Preclinical (animal, in vitro, computational): 12 of 892020, Reviews and meta-analyses: 25 of 892020, Other and not yet classified: 7 of 892021, Human clinical research: 43 of 742021, Preclinical (animal, in vitro, computational): 9 of 742021, Reviews and meta-analyses: 18 of 742021, Other and not yet classified: 4 of 742022, Human clinical research: 39 of 722022, Preclinical (animal, in vitro, computational): 14 of 722022, Reviews and meta-analyses: 13 of 722022, Other and not yet classified: 6 of 722023, Human clinical research: 62 of 922023, Preclinical (animal, in vitro, computational): 13 of 922023, Reviews and meta-analyses: 16 of 922023, Other and not yet classified: 1 of 922024, Human clinical research: 73 of 1272024, Preclinical (animal, in vitro, computational): 19 of 1272024, Reviews and meta-analyses: 26 of 1272024, Other and not yet classified: 9 of 1272025, Human clinical research: 88 of 1612025, Preclinical (animal, in vitro, computational): 19 of 1612025, Reviews and meta-analyses: 41 of 1612025, Other and not yet classified: 13 of 1612026 (to date), Human clinical research: 102 of 1812026 (to date), Preclinical (animal, in vitro, computational): 17 of 1812026 (to date), Reviews and meta-analyses: 52 of 1812026 (to date), Other and not yet classified: 10 of 181Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05010015020020102014201820222026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
201001102
201130104
201240004
201300303
2014706417
201512322441
201616124243
201717418140
201830621764
2019361610668
2020451225789
202143918474
2022391413672
2023621316192
20247319269127
202588194113161
2026 (to date)102175210181

Study types

Observational human study297
Randomized controlled trial171
Review164
Meta-analysis81
Animal study76
Editorial, letter or other69
Case report64
Systematic review52
Other clinical trial45
Computational study42
In vitro study16
Not yet classified5

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health985
Endocrinology715
Obesity and weight management228
Cardiovascular191
Gastrointestinal105
Neurological and mental health104
Reproductive and sexual health53
Immune system40
Musculoskeletal22
Cognitive health21
Oncology21
Dermatology15

Registered clinical trials

12 of 85 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 95 · Recruiting: 8 · Unknown status: 8 · Active, not recruiting: 3 · Not yet recruiting: 3 · Terminated: 3 · Enrolling by invitation: 1
Phase not applicable: 16 · Phase 1: 22 · Phase 1 / Phase 2: 2 · Phase 2: 23 · Phase 2 / Phase 3: 2 · Phase 3: 34 · Phase 4: 22

TrialStatusPhaseStartedResults
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNCT07677891 · 60 enrolledNot yet recruitingPhase 22026-10—
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336 · 170 enrolledRecruitingPhase 32026-07—
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · 468 enrolledNot yet recruitingPhase 42026-05—
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.NCT07417631 · 300,000 enrolledCompletedPhase not applicable2026-02—
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)NCT07417618 · 60,000 enrolledCompletedPhase not applicable2026-01—
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495 · 120,000 enrolledCompletedPhase not applicable2026-01—
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813 · 20 enrolledCompletedPhase 12025-12—
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisNCT07282041 · 130 enrolledRecruitingPhase 2, Phase 32025-12—
Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesNCT07834398 · 150 enrolledCompletedPhase 32025-11—
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialNCT07820111 · 159 enrolledCompletedPhase 32025-10—
A Phase 3 Study of HS-20094 in Patients With T2DMNCT07156539 · 546 enrolledNot yet recruitingPhase 32025-09—
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusNCT07319286 · 50 enrolledEnrolling by invitationPhase 1, Phase 22025-08—
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962 · 92 enrolledCompletedPhase 42025-05—
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminNCT07109700 · 216 enrolledRecruitingPhase 22025-04—
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · 55 enrolledRecruitingPhase 32025-01—
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsNCT07325435 · 60 enrolledActive, not recruitingPhase 42024-12—
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaNCT07370922 · 80 enrolledCompletedPhase 22024-11—
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT06779929 · 70,000 enrolledCompletedPhase not applicable2024-11—
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims DataNCT07088718 · 44,671 enrolledCompletedPhase not applicable2024-10—
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskNCT07096063 · 887,132 enrolledCompletedPhase not applicable2024-10—
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyNCT06533527 · 69 enrolledCompletedPhase 42024-07Posted
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966 · 600 enrolledActive, not recruitingPhase 32024-07—
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusNCT06235086 · 632 enrolledCompletedPhase 32024-04—
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryNCT06324461 · 372 enrolledRecruitingPhase 42024-03—
A Study of HS-20094 in Patients With T2DMNCT06901648 · 275 enrolledCompletedPhase 22024-02—
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes MellitusNCT06148649 · 234 enrolledCompletedPhase 22023-12—
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNCT05140694 · 135 enrolledUnknown statusPhase 42023-12—
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707 · 47 enrolledRecruitingPhase 22023-10—
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDNCT07309094 · 250 enrolledRecruitingPhase not applicable2023-09—
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With ObesityNCT06331286 · 60 enrolledUnknown statusPhase not applicable2023-09—
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129 · 623 enrolledCompletedPhase 32023-01—
A Study of IBI362 in Participants With Type 2 DiabetesNCT05606913 · 731 enrolledCompletedPhase 32023-01—
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaNCT05659537 · 212 enrolledCompletedPhase 42022-12Posted
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039 · 282 enrolledCompletedPhase 42022-11Posted
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusNCT05516966 · 64 enrolledCompletedPhase 12022-10—
A Study of TG103 Injection in Type 2 Diabetes SubjectsNCT05348122 · 240 enrolledUnknown statusPhase 22022-06—
A Study of LY3532226 in Participants With Type 2 Diabetes MellitusNCT05407961 · 90 enrolledCompletedPhase 12022-06—
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT05377333 · 94 enrolledCompletedPhase 12022-06—
A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese SubjectsNCT05459285 · 68 enrolledCompletedPhase 12022-05—
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseNCT05254418 · 7 enrolledCompletedPhase 22022-03Posted
Basal Plus GLP1-ra on Glycemic Variability in CKDNCT05218915 · 95 enrolledCompletedPhase 42022-01—
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic NephropathyNCT06182891 · 300 enrolledCompletedPhase not applicable2021-10—
A Study of LY3502970 in Participants With Type 2 Diabetes MellitusNCT05048719 · 383 enrolledCompletedPhase 22021-09Posted
A Study of IBI362 in Chinese Patients With Type 2 DiabetesNCT04965506 · 252 enrolledCompletedPhase 22021-09—
Perioperative Stress Hyperglycemia in General and Vascular Surgery PatientsNCT04862234 · 16 enrolledTerminatedPhase 42021-08Posted
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917 · 781,430 enrolledActive, not recruitingPhase not applicable2021-08—
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceNCT04731272 · 30 enrolledRecruitingPhase 22021-07—
GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)NCT04876027 · 68 enrolledCompletedPhase 42021-05—
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 · 281 enrolledCompletedPhase 22021-05Posted
Effects of Glucagon-Like Peptide-1 Analogs on SexualityNCT04687514 · 26 enrolledCompletedPhase 22021-05—

The 50 most recently started of 121 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Glucagon-like peptide-1 receptor agonists and risk of arrhythmias: A network meta-analysis.

    Heart rhythm · October 26, 2026 · Meta-analysis · cited 0 times

    PMID 42933519 · DOI 10.1016/j.hrthm.2026.10.052 · Reviews and meta-analyses

  2. Glucagon-like receptor-1 agonists and impotence: A meta-analysis.

    World journal of methodology · September 20, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42626264 · DOI 10.5662/wjm.119385 · Reviews and meta-analyses

  3. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.

    Drugs · September 12, 2026 · Meta-analysis · cited 1 times · open access

    PMID 42730869 · DOI 10.1007/s40265-026-02365-3 · Reviews and meta-analyses

  4. Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.

    Frontiers in endocrinology · September 11, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42798476 · DOI 10.3389/fendo.2026.1934027 · Reviews and meta-analyses

  5. Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.

    PeerJ · September 8, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42729958 · DOI 10.7717/peerj.21713 · Reviews and meta-analyses

  6. Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · August 4, 2026 · Meta-analysis · cited 0 times

    PMID 42551699 · DOI 10.1016/j.eprac.2026.07.018 · Reviews and meta-analyses

  7. Incorporating estimands into meta-analyses of clinical trials.

    Research synthesis methods · July 30, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42527984 · DOI 10.1017/rsm.2026.10107 · Reviews and meta-analyses

  8. Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

    Diabetology & metabolic syndrome · July 24, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42897592 · DOI 10.1186/s13098-026-02248-3 · Reviews and meta-analyses

  9. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.

    JAMA internal medicine · May 1, 2026 · Meta-analysis · cited 23 times · open access

    PMID 41770554 · DOI 10.1001/jamainternmed.2025.8222 · Reviews and meta-analyses

  10. Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials.

    Canadian journal of diabetes · April 10, 2026 · Meta-analysis · cited 0 times

    PMID 41967797 · DOI 10.1016/j.jcjd.2026.04.001 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

    Lancet (London, England) · June 9, 2019 · Randomized controlled trial · cited 3,146 times · open access

    PMID 31189511 · DOI 10.1016/s0140-6736(19)31149-3 · Human clinical research

  2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

    The lancet. Diabetes & endocrinology · August 14, 2019 · Meta-analysis · cited 1,658 times · open access

    PMID 31422062 · DOI 10.1016/s2213-8587(19)30249-9 · Reviews and meta-analyses

  3. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

    Molecular metabolism · October 14, 2020 · Review · cited 1,624 times · open access

    PMID 33068776 · DOI 10.1016/j.molmet.2020.101102 · Reviews and meta-analyses

  4. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

    Lancet (London, England) · October 4, 2018 · Randomized controlled trial · cited 815 times

    PMID 30293770 · DOI 10.1016/s0140-6736(18)32260-8 · Human clinical research

  5. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

    The lancet. Diabetes & endocrinology · February 1, 2018 · Randomized controlled trial · cited 788 times

    PMID 29397376 · DOI 10.1016/s2213-8587(18)30024-x · Human clinical research

Latest publications

  1. Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial.

    Diabetes, obesity & metabolism · November 9, 2026 · Observational human study · cited 0 times · open access

    PMID 43003406 · DOI 10.1111/dom.71515 · Human clinical research

  2. GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study.

    Balkan medical journal · November 2, 2026 · Observational human study · cited 0 times · open access

    PMID 42969666 · DOI 10.4274/balkanmedj.galenos.2026.2026-7-49 · Human clinical research

  3. The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents.

    Bone · November 2, 2026 · Review · cited 0 times

    PMID 42971377 · DOI 10.1016/j.bone.2026.118160 · Reviews and meta-analyses

  4. Effects of glucagon-like peptide-1 analogs on prolactin levels: A secondary analysis of a randomized, double-blind, placebo-controlled crossover trial.

    Journal of neuroendocrinology · November 1, 2026 · Randomized controlled trial · cited 0 times · open access

    PMID 42985994 · DOI 10.1111/jne.70308 · Human clinical research

  5. Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance.

    Pharmacoepidemiology and drug safety · November 1, 2026 · Observational human study · cited 0 times · open access

    PMID 42946127 · DOI 10.1002/pds.70517 · Human clinical research

  6. Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model.

    Alzheimer's & dementia (New York, N. Y.) · October 28, 2026 · Animal study · cited 0 times · open access

    PMID 42959452 · DOI 10.1002/trc2.70336 · Animal studies

  7. GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways.

    British journal of pharmacology · October 28, 2026 · Animal study · cited 0 times

    PMID 42950887 · DOI 10.1111/bph.70720 · Animal studies

  8. Effect of dulaglutide on functional and structural MRI changes during cigarette smoking cessation.

    Brain communications · October 27, 2026 · Randomized controlled trial · cited 0 times · open access

    PMID 43011533 · DOI 10.1093/braincomms/fcag410 · Human clinical research

  9. Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis.

    Diabetes care · October 27, 2026 · Observational human study · cited 0 times

    PMID 42937520 · DOI 10.2337/dc26-2069 · Human clinical research

  10. Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study.

    Transplantation · October 27, 2026 · Observational human study · cited 0 times

    PMID 42934184 · DOI 10.1097/tp.0000000000005945 · Human clinical research

Browse all 1,082 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Dulaglutide; LY2189265; Trulicity

((TITLE_ABS:"Dulaglutide" OR CHEM:"Dulaglutide") OR (TITLE_ABS:"LY2189265" OR CHEM:"LY2189265" OR TITLE_ABS:"LY 2189265" OR CHEM:"LY 2189265") OR (TITLE_ABS:"Trulicity" OR CHEM:"Trulicity")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Dulaglutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/dulaglutide